Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**68Ga-A3** is an investigational gallium-68 radiolabeled ACE2-targeting PET/CT imaging probe developed by Peking Union Medical College Hospital. It is designed to bind angiotensin-converting enzyme 2 and enable noninvasive visualization of ACE2 expression, including in lung cancer lesions. The agent has been evaluated by intravenous administration in an early-phase clinical study for diagnostic PET/CT imaging in participants with lung cancer and healthy volunteers. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06194630))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-A3.